Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis

Bibliographic Details
Main Authors: Xiewei Huang, Yushuai Yu, Shiping Luo, Wenfen Fu, Jie Zhang, Chuangui Song
Format: Article
Language:English
Published: BMC 2024-02-01
Series:BMC Cancer
Online Access:https://doi.org/10.1186/s12885-024-11932-4

Internet

https://doi.org/10.1186/s12885-024-11932-4

Similar Items